We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Dot Compliance, a leading provider of eQMS compliance solutions for the life sciences sector, has introduced an industry-first, ready-to-use AI-Based electronic Quality Management System for life sciences, powered
Masimo has received De Novo authorisation for its Masimo Opioid Halo system from the US Food and Drug Administration (FDA) to detect opioid-induced respiratory depression. According to the
Laborie Medical Technologies has introduced the alpHaONE system, designed specifically to diagnose gastroesophageal reflux disease (GERD). According to the US-based diagnostic and therapeutic medical technology company, alpHaONE is
Enovis Corporation, an innovation-driven, medical technology growth company, today announced a definitive agreement to acquire Novastep, a subsidiary of Amplitude Surgical SA, and global developer of clinically proven
Pixium Vision has secured breakthrough device designation from the US Food and Drug Administration (FDA) for its Prima System for the treatment of patients with atrophic dry age-related
In vitro diagnostics products maker Fujirebio has launched the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assays for research use only (RUO) for the fully automated LUMIPULSE G
Lucid Diagnostics, a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed, announced that, yesterday, the MolDX Program (“MolDX”) published a Future Effective Local Coverage Determination
Study results show that Coloplast’s new intermittent male catheter with 80+ micro-holes, Luja, achieved complete bladder emptying in one free flow in 90% of catheterisations, while Hollister’s 2-eyelet
US-based medical device company HistoSonics has announced treatment of the first kidney patient using its histotripsy non-invasive platform and sonic beam therapy. The first treatment, which was for
Exai Bio has signed a collaboration agreement with Quantum Leap Healthcare Collaborative (QLHC) to expand the use of its RNA-based liquid biopsy platform in the I-SPY 2 trial